VSIR and colorectal cancer: In consideration of elevated expression of VISTA or VSIG-3 in many cancers, such as colorectal cancer (CRC), HCC, and intestinal-type gastric cancers, the blockade of the VISTA/VSIG-3 pathway can work as a new target for immune checkpoint therapy.